Innoviva, Inc. (INVA)

Market Cap	1.53B +16.3%
Revenue (ttm)	440.00M +18.8%
Net Income	357.24M +824.3%
EPS	4.31 +708.3%
Shares Out	72.25M
PE Ratio	4.92
Forward PE	11.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,107
Open	21.16
Previous Close	21.34
Day's Range	21.13 - 21.41
52-Week Range	16.52 - 25.15
Beta	0.33
Analysts	Buy
Price Target	35.00 (+65.06%)
Earnings Date	Aug 5, 2026

About INVA

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2004
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: INVA
• Website: https://www.inva.com

Financial Performance

In 2025, Innoviva's revenue was $411.33 million, an increase of 14.67% compared to the previous year's $358.71 million. Earnings were $271.17 million, an increase of 1059.22%.

Analyst Summary

According to 4 analysts, the average rating for INVA stock is "Buy." The 12-month stock price target is $35.0, which is an increase of 65.06% from the latest price.

Price Target

$35.0

(65.06% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 9, 2026

Data Sources Report a data error